Clinical diagnosis of drug-induced autoimmune-like hepatitis

VernacularTitle:药物诱导的自身免疫样肝炎的临床诊断
Author: Yongping LIU ¹ ; Yaojie SHEN ²
Author Information

1. Department of Hepatology， Hangzhou Xixi Hospital Affiliated to Zhejiang University of Chinese Medicine， Hangzhou 310023， China
2. Clinical Experiment Center， Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine， Hangzhou 310003， China
Publication Type:Review
Keywords: Drug-induced Autoimmune-like Hepatitis; Drug-induced Liver Injury; Hepatitis， Autoimmune; Diagnosis
From: Journal of Clinical Hepatology 2025;41(3):542-546
CountryChina
Language:Chinese
Abstract: Some patients with drug-induced liver injury （DILI） may present with similar features to patients with autoimmune hepatitis （AIH）， and such cases are defined as drug-induced autoimmune-like hepatitis （DI-ALH）. In 2022， the European Association for the Study of the Liver discussed the nomenclature， diagnosis， and treatment of DI-ALH and put forward expert opinions to establish the criteria for clinical diagnosis. However， the clinical diagnosis of DI-ALH remains complex and difficult， and there is no direct evidence for the link between drug intake and the body’s immune progression. Therefore， this article reviews the research advances in the diagnosis of DI-ALH from the four aspects of clinical phenotype， pathological diagnosis， diagnostic score， and clinical prognosis.